NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

BACKGROUND: Because of the shortage of ideal cell surface antigens, the development of T-cell receptor (TCR)-engineered T cells (TCR-T) that target intracellular antigens such as NY-ESO-1 is a promising approach for treating patients with solid tumors. However, endogenous TCRs in vector-transduced T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihara, Mikiya, Kitano, Shigehisa, Kageyama, Shinichi, Miyahara, Yoshihiro, Yamamoto, Noboru, Kato, Hidefumi, Mishima, Hideyuki, Hattori, Hiroyoshi, Funakoshi, Takeru, Kojima, Takashi, Sasada, Tetsuro, Sato, Eiichi, Okamoto, Sachiko, Tomura, Daisuke, Nukaya, Ikuei, Chono, Hideto, Mineno, Junichi, Kairi, Muhammad Faris, Diem Hoang Nguyen, Phuong, Simoni, Yannick, Nardin, Alessandra, Newell, Evan, Fehlings, Michael, Ikeda, Hiroaki, Watanabe, Takashi, Shiku, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244667/
https://www.ncbi.nlm.nih.gov/pubmed/35768164
http://dx.doi.org/10.1136/jitc-2021-003811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244667/
https://www.ncbi.nlm.nih.gov/pubmed/35768164
http://dx.doi.org/10.1136/jitc-2021-003811

Ejemplares similares